2432

(Albany, New York) – October 19, 2026: As per DelveInsight’s assessment, globally, Vitiligo pipeline constitutes 20+ key companies continuously working towards developing 25+ Vitiligo treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Vitiligo Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products

The Key Chronic Kidney Disease Companies in the market include – Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others . (Albany, New York) – October 15, 2026: DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney

The Key MASH Companies in the market include – Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, AstraZeneca, Boehringer Ingelheim, Can-Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others.

The Key Endometrial Cancer Companies in the market include – Eli Lilly, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others. (Albany, New York) – October 15, 2026: DelveInsight’s “Endometrial Cancer Market

(Albany, New York) – October 09, 2026: DelveInsight’s “Bulimia Nervosa Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of bulimia nervosa, covering historical and forecasted epidemiology, current treatment practices, market trends, and the therapeutic landscape across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key

Polycythemia Vera is a myeloproliferative neoplastic disorder involving uncontrolled red blood cell production resulting in elevated red blood cell mass, often with concurrent stimulation of myeloid and megakaryocytic lineages leading to increased white blood cell and platelet production. (Albany, New York) – 21st Sep 2026 – DelveInsight’s “Polycythemia Vera Pipeline Insight, 2026” report provides comprehensive insights